CERO THERAPEUTICS Proposes Reverse Split, Dilutive Issuance, and Share Increase

TL;DR

**CEROW is scrambling to stay listed and raise cash, but these proposals reek of desperation and will likely crush existing shareholders with massive dilution.**

AI Summary

CERO THERAPEUTICS HOLDINGS, INC. (CEROW) is convening a Special Meeting of Stockholders on December 19, 2025, to address critical strategic and financial proposals. The company seeks approval for a reverse stock split, ranging from one-for-40 to one-for-150, aimed at potentially increasing its stock price and maintaining Nasdaq listing compliance. Additionally, CEROW is requesting approval for the issuance of common stock upon conversion of Series E convertible preferred stock, issued in a private placement in October 2025, at a price below Nasdaq's 'minimum price' rule. The company also proposes to amend its 2024 Equity Incentive Plan to increase the shares available for issuance by an additional 32,000,000 shares, which could dilute existing shareholders. Finally, stockholders will vote on an adjournment proposal to ensure sufficient votes for the other three proposals. These actions collectively indicate a company facing significant financial and operational challenges, including potential delisting from Nasdaq, and seeking to recapitalize and incentivize its workforce.

Why It Matters

This DEF 14A filing reveals CERO THERAPEUTICS' urgent need to address its stock price and capital structure, directly impacting investor confidence and potential for future financing. A reverse stock split, while potentially boosting per-share price, often signals underlying financial distress and can lead to further stock price declines post-split. The proposed issuance of Series E preferred stock below Nasdaq's minimum price suggests a challenging fundraising environment and could significantly dilute existing shareholders. For employees, the increased equity incentive plan offers potential retention benefits but also adds to dilution concerns. Competitively, these moves highlight CEROW's struggle to maintain market standing and attract capital compared to more stable biotech peers.

Risk Assessment

Risk Level: high — The proposed reverse stock split, with a wide ratio of one-for-40 to one-for-150, indicates a severe need to increase share price, likely to avoid Nasdaq delisting, which is a high-risk signal. The approval for issuing shares from the October 2025 Private Placement below Nasdaq's 'minimum price' rule 5635(d) suggests significant dilution for existing shareholders and a distressed capital raise. Furthermore, increasing the 2024 Equity Incentive Plan by an additional 32,000,000 shares will exacerbate dilution.

Analyst Insight

Investors should carefully evaluate the potential for significant dilution from the Series E preferred stock conversion and the increased equity incentive plan. Consider selling CEROW shares before the reverse stock split, as such actions often precede further stock price declines and indicate severe financial distress. Monitor the outcome of the Special Meeting on December 19, 2025, for definitive impacts.

Key Numbers

• 1-for-40 — Minimum reverse stock split ratio (Proposed minimum ratio for combining outstanding shares of common stock)
• 1-for-150 — Maximum reverse stock split ratio (Proposed maximum ratio for combining outstanding shares of common stock)
• 32,000,000 — Additional shares for 2024 Equity Incentive Plan (Proposed increase in shares available for issuance under the 2024 Plan)
• 20,802,671 — Shares outstanding on record date (Number of Common Stock shares entitled to vote as of November 14, 2025)
• November 14, 2025 — Record Date (Date for determining stockholders eligible to vote at the Special Meeting)
• December 19, 2025 — Special Meeting Date (Date the 2025 Special Meeting of Stockholders will be held)

Key Players & Entities

• CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant and company holding the Special Meeting
• Chris Ehrlich (person) — Chairman, Chief Executive Officer, and Director of CERO THERAPEUTICS HOLDINGS, INC.
• Nasdaq (regulator) — Stock exchange whose listing rules (5635, 5635(d)) are relevant to the proposals
• Okapi Partners, LLC (company) — Proxy solicitor for CERO THERAPEUTICS HOLDINGS, INC.
• $0.0001 (dollar_amount) — Par value per share of Common Stock and Series E convertible preferred stock
• 20,802,671 (dollar_amount) — Shares of Common Stock outstanding and entitled to vote as of November 14, 2025
• 32,000,000 (dollar_amount) — Additional shares proposed for issuance under the 2024 Equity Incentive Plan
• November 14, 2025 (date) — Record date for stockholders entitled to vote at the Special Meeting
• December 19, 2025 (date) — Date of the 2025 Special Meeting of Stockholders
• October 2025 (date) — Month when Series E convertible preferred stock was issued in a private placement

FAQ

Risk Factors

• Nasdaq Delisting Risk [high — regulatory]: The company's common stock and public warrants are at risk of delisting from the Nasdaq Stock Market. The proposed reverse stock split aims to increase the stock price to meet Nasdaq's minimum price requirement, but failure to do so could lead to delisting, impacting liquidity and investor confidence.
• Dilution from Equity Issuance [high — financial]: The company is seeking approval to issue common stock upon conversion of Series E convertible preferred stock at a price below Nasdaq's minimum price rule. Additionally, an increase of 32,000,000 shares under the 2024 Equity Incentive Plan is proposed, which could significantly dilute existing shareholders.
• Dependence on Strategic Proposals [high — operational]: The company's ability to continue operations and meet its financial obligations is heavily dependent on the approval of critical strategic proposals at the Special Meeting, including the reverse stock split and equity issuances. Failure to secure these approvals could jeopardize the company's future.
• Cash Sufficiency and Future Funding [medium — financial]: The company is seeking additional cash and its existing cash, cash equivalents, and equity securities may not be sufficient to fund future operating expenses and capital expenditure requirements, including drug development. This highlights a potential ongoing need for external financing.

Industry Context

CERO THERAPEUTICS operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often face significant R&D costs, long development timelines, and stringent regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and the ability to secure ongoing funding to advance drug candidates through development and potential commercialization.

Regulatory Implications

The company faces significant regulatory risk related to Nasdaq listing compliance. Failure to meet the minimum bid price requirement could lead to delisting, impacting liquidity and investor access. The proposed actions, including the reverse stock split and equity issuance, are directly aimed at mitigating these regulatory concerns.

What Investors Should Do

1. Review the proposed reverse stock split ratios (1-for-40 to 1-for-150) and understand the potential impact on share count and per-share value.
2. Evaluate the implications of approving the issuance of common stock upon conversion of Series E preferred stock, especially concerning dilution and the price at which it was issued.
3. Assess the proposed increase of 32,000,000 shares under the 2024 Equity Incentive Plan and its potential dilutive effect.
4. Consider the company's overall financial health and its reliance on these proposals for continued operation and Nasdaq listing.

Key Dates

• 2025-12-19: Special Meeting of Stockholders — Stockholders will vote on critical proposals including a reverse stock split, equity issuance, and amendments to the equity incentive plan, which are crucial for the company's strategic direction and Nasdaq compliance.
• 2025-11-14: Record Date — Determines which stockholders are eligible to vote at the Special Meeting on December 19, 2025.
• 2025-10: Series E convertible preferred stock private placement — This private placement resulted in the issuance of convertible preferred stock at a price below Nasdaq's minimum price rule, necessitating the current proposals to address potential compliance issues.
• 2023-06-04: Business Combination Agreement — This agreement outlines the terms of the business combination involving Legacy CERo, Phoenix Biotech Acquisition Corp., and PBCE Merger Sub, Inc., forming the basis of the current corporate structure.

Glossary

DEF 14A

A proxy statement filed with the U.S. Securities and Exchange Commission (SEC) by public companies soliciting shareholder votes on important corporate matters. (This document contains the proposals and information relevant to the upcoming Special Meeting of Stockholders.)

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (CERO THERAPEUTICS is proposing a reverse stock split to increase its stock price and potentially regain compliance with Nasdaq listing requirements.)

Nasdaq Minimum Price Rule

A rule set by the Nasdaq Stock Market that requires listed securities to maintain a minimum bid price, typically $1.00 per share, to remain listed. (CERO THERAPEUTICS is seeking to address a potential violation of this rule through its proposed reverse stock split and equity issuance strategy.)

Equity Incentive Plan

A plan established by a company to grant stock options, restricted stock, or other equity-based awards to employees, directors, and consultants as a form of compensation and incentive. (The company is proposing to increase the number of shares available under its 2024 Equity Incentive Plan, which could lead to dilution.)

Series E convertible preferred stock

A class of preferred stock that can be converted into a predetermined number of common stock shares, issued in a private placement. (The conversion of this stock is a key proposal, as it was issued below Nasdaq's minimum price, requiring shareholder approval for the resulting common stock issuance.)

Year-Over-Year Comparison

Information regarding comparison to a previous filing is not available in the provided text. The DEF 14A focuses on the upcoming Special Meeting and the proposals to be voted upon, rather than a year-over-year financial comparison.

Key Financial Figures

• $0.0001 — g shares of our common stock, par value $0.0001 per share ("Common Stock"), into a less

Filing Documents

• ea0262220-02.htm (DEF 14A) — 801KB
• tcero_logo.jpg (GRAPHIC) — 49KB
• tproxy_001.jpg (GRAPHIC) — 1521KB
• tproxy_002.jpg (GRAPHIC) — 1146KB
• 0001213900-25-115783.txt ( ) — 7644KB
• cero-20251128.xsd (EX-101.SCH) — 7KB
• cero-20251128_def.xml (EX-101.DEF) — 2KB
• cero-20251128_lab.xml (EX-101.LAB) — 22KB
• ea0262220-02_htm.xml (XML) — 2KB

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 28 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 50

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 52 STOCKHOLDER PROPOSALS 54 STOCKHOLDER COMMUNICATIONS 55 HOUSEHOLDING 55 SOLICITATION OF PROXIES 55 ANNUAL REPORT 56 OTHER MATTERS 56 WHERE YOU CAN FIND ADDITIONAL INFORMATION 56 APPENDIX A: CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CERO THERAPEUTICS HOLDINGS, INC. A-1 APPENDIX B: FOURTH AMENDMENT TO THE CERO THERAPEUTICS HOLDINGS, INC. 2024 EQUITY INCENTIVE PLAN B-1 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This proxy statement (this "proxy statement") contains forward -looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this proxy statement, including statements regarding the Company's future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development ("R&D") costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward -looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company's control and may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward -looking statements. In some cases, you can identify forward -looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other

View Full Filing

View this DEF 14A filing on SEC EDGAR